ONCAlert | Upfront Therapy for mRCC

Multiple Myeloma VIEW MORE >>

The FDA granted Priority Review to the Biologics License Application for belantamab mafodotin, an anti–B cell maturation antigen monoclonal antibody for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapies included an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, GlaxoSmithKline plc announced in a press release.
 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.